David Huang | Chief Medical Officer
Motif Bio

David Huang, Chief Medical Officer, Motif Bio

Dr. Huang is the Chief Medical Officer at Motif Bio, and the former Chief Medical Officer at ContraFect Corporation. Dr. Huang has also led drug development groups in anti-infectives at Pfizer and Boehringer-Ingelheim. Dr. Huang has 15 years of clinical, academic and research experience in medicine and in the subspeciality of infectious diseases. His research interests include bacteriology and virology, especially the epidemiology, pathogenesis, and treatment of multi-drug resistant organisms. He is well versed in the design, execution and close out of Phase I – III clinical trials for both antibacterials and antiviral agents. Dr. Huang completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas at Southwestern and fellowship in infectious diseases at Baylor College of Medicine.

Appearances:



World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 17:10

Keynote Address: Updates to Iclaprim clinical development program

  • Nearing commercialization: Updated data from two phase 3 clinical trials
  • New data from non-clinical trials including in-vitro testing, global surveillance, animal testing, different indications and pathogens
  • Navigating the regulatory approval process: filing NDA and NAH to the FDA and EMA respectively
  • What’s next? Looking to future studies to address high unmet medical needs
last published: 12/Oct/18 20:55 GMT

back to speakers